目的 探讨安罗替尼联合TP方案治疗老年非小细胞肺癌患者的效果及其对CA125、MALAT1水平的影响。方法 选取2019年5月-2019年12月青岛市妇女儿童医院和青岛市市立医院治疗的非小细胞肺癌患者98例作为研究对象，将患者随机分为对照组和观察组，每组各49例。对照组患者治疗第1天将紫杉醇注射液135 mg/m²溶于生理盐水500 mL静脉滴注，3 h内完成。在治疗1~3 d后将顺铂注射液溶于生理盐水250 mL中静脉滴注，1 h完成。治疗21 d作为1个周期，治疗3个周期。观察组患者在对照组的基础上服用盐酸安罗替尼胶囊，12 mg/次，1次/d，服用2周后休息1周，治疗共计3个周期。观察两组的临床疗效，同时比较两组治疗前后的CA125、MALAT1水平及免疫功能指标。结果 治疗后，观察组患者的肿瘤控制率为46.94%，显著高于对照组的26.53%（P<0.05）。治疗后，两组CA125水平显著降低，MALAT1水平显著升高（P<0.05）；且观察组患者的CA125显著低于对照组，MALAT1显著高于对照组（P<0.05）。治疗后，两组患者的CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺比值及NK细胞均显著下降（P<0.05）；观察组患者CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺比值及NK细胞显著高于对照组（P<0.05）。结论 安罗替尼联合TP方案化疗治疗非小细胞肺癌效果显著，可显著改善患者CA125水平及MALAT1的表达，安全性较好。

Objective To investigate the effect of anlotinib combined with TP chemotherapy in treatment of elderly patients with nonsmall cell lung cancer and the influence on the levels of CA125 and MALAT1. Methods A total of 98 patients with NSCLC who were treated in Qingdao Women's and Children's Hospital and Qingdao Municipal Hospital from May 2019 to December 2019 were selected as the research subjects, and the patients were randomly divided into control group and observation group, with 49 patients in each group. Patients in the control group were iv administered with Paclitaxel Injection, 135 mg/m² dissolved in 500 mL normal saline intravenously on the first day of treatment, which was completed within 3 h. After 1 to 3 days of treatment, Cisplatin Injection was dissolved in 250 mL of normal saline and intravenously dripping, which was completed in 1 h. The treatment lasted for 21 d as one cycle, and the treatment lasted for 3 cycles. Patients in the observation group were po administered with Anlotinib Hydrochloride Capsules on the basis of control group, 12 mg/time, once daily. The treatment lasted for 3 months after 2 weeks of treatment with 1 week rest. The clinical efficacy of two groups was observed, and the levels of CA125, MALAT1 and immune function were compared before and after treatment. Results After treatment, the tumor control rate of observation group was 46.94%, significantly higher than 26.53% of control group (P<0.05). After treatment, the level of CA125 in two groups was significantly decreased, but MALAT1 level was significantly increased (P<0.05). After treatment, the level of CA125 in observation group was significantly lower than control group, but MALAT1 was significantly higher than control group (P<0.05). After treatment, the ratio of CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ and the percentage of NK cells in two groups were significantly decreased (P<0.05). The ratio of CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ and NK cell percentage in observation group were significantly higher than those in control group (P<0.05). Conclusion Amlotinib combined with TP chemotherapy has a significant effect in treatment of NSCLC, which can significantly improve the level of CA125 and the expression of MALAT1 in patients with good safety.

R971